Why the study?
Does ouabain or digoxin reduce ischemic injury in isolated perfused rat hearts?
Does ouabain or digoxin reduce ischemic injury in isolated perfused rat hearts?
Ouabain and digoxin demonstrated cardioprotective effects against ischemia-reperfusion injury in isolated rat hearts, which correlated with ERK1/2 activation rather than Na, K-ATPase inhibition.
Hypothesis-generating for cardiac glycoside cardioprotection in rat hearts; leaves open translation to clinical ischemia-reperfusion injury.
This work was aimed at determining the cardioprotective effect of digitalis glycosides in rat heart, and to relate it with Na, K-ATPase inhibition and ERK1/2 activation. Isolated working rat hearts were perfused in the presence of ouabain or digoxin, which were used at concentrations ranging from 10 to 10 M. The hearts were then subjected to 30 minutes of global normothermic ischemia followed by 120 minutes of retrograde reperfusion; irreversible tissue injury was determined on the basis of triphenyltetrazolium chloride staining. Significant cardioprotection was observed with 10 M and 10 M ouabain (ischemic injury averaged 7.0 +/- 3.5% and 8.3 +/- 0.6% versus 37.3 +/- 2.0% in controls, P < 0.01 in each case). Hearts treated with digoxin showed decreased ischemic injury at 10 M and 10 M (18.0 +/- 1.5% and 14.2 +/- 1.0%, P < 0.01 versus control in both cases). In parallel experiments, ERK2 phosphorylation was increased by 10 to 10 M ouabain, while ERK1 and ERK2 phosphorylation was increased by 10 to 10 M digoxin. The cardioprotective effect was not related to Na, K-ATPase inhibition, since Rbuptake was not significantly different between control and treated hearts.
No takes yet. Share an insight, caveat, or question.
D’Urso et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: